Inhibition of Proliferation of Non-small Cell Lung Cancer Cells by a bFGF Antagonist Peptide
- 211 Downloads
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Basic fibroblast growth factor (bFGF) is up-regulated in NSCLC patients and plays an important role in tumor growth. In this paper, we attempt to evaluate the therapeutic potential of bFGF binding peptide (named as P7) using as a potent bFGF antagonist via exploration of its anti-proliferation effect on NSCLC cells. Our experiments showed that P7 peptide inhibited bFGF-stimulated proliferation of NSCLC cell lines including A549, H1299, and H460. The inhibitory mechanism of P7 involved cell cycle arrest at the G0/G1phase caused by suppression of cyclin D1, blockage of the activation of Erk1/2, P38, Akt, and inhibition of bFGF internalization. Strategies using bFGF antagonist peptides with potent anti-proliferation property may have therapeutic potential in NSCLC.
KeywordsbFGF antagonist peptide Proliferation Internalization Non-small cell lung cancer
This work was supported by grants from the National Natural Science Foundation of China (30973671, 81071800), the Guangdong Provincial Science and Technology Program (2010B060900040), the Natural Science Foundation of Guangdong Province of China (9151064001000031), the Natural Science Foundation of Zhejiang Province of China (Y2090292, Y4090379), the Science and Technology Planning Project of Wenzhou (Y20090244), the Fundamental Research Funds for the Central Universities (X. Wu), Guangdong Provincial ‘‘Thousand-Hundred-Ten Talent Project’’ (X. Wu), and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Jinan University.
Conflict of interest
The authors declare no conflicts of interest.
- Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17(10):3188–3194PubMedGoogle Scholar
- Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60(3):615–622; discussion 622–623Google Scholar
- Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15(12):1782–1789. doi: 10.1093/annonc/mdh476 PubMedCrossRefGoogle Scholar
- Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28(10):1721–1726. doi: 10.1200/JCO.2009.24.9342 PubMedCrossRefGoogle Scholar
- Mansukhani A, Dell’Era P, Moscatelli D, Kornbluth S, Hanafusa H, Basilico C (1992) Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. Proc Natl Acad Sci USA 89(8):3305–3309PubMedCrossRefGoogle Scholar
- Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE (2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75(1):196–207. doi: 10.1124/mol.108.049544 PubMedCrossRefGoogle Scholar
- Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92(10):2639–2647PubMedCrossRefGoogle Scholar